0001628280-26-059444.txt : 20260828 0001628280-26-059444.hdr.sgml : 20260828 20260828174002 ACCESSION NUMBER: 0001628280-26-059444 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260827 FILED AS OF DATE: 20260828 DATE AS OF CHANGE: 20260828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Curran Terrie CENTRAL INDEX KEY: 0001690298 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39186 FILM NUMBER: 261341732 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 320 WEST 37TH STREET, 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001787306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 812974255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 805-418-5006 MAIL ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Arcutis, Inc. DATE OF NAME CHANGE: 20190905 4 1 wk-form4_1787953199.xml FORM 4 X0609 4 2026-08-27 0 0001787306 Arcutis Biotherapeutics, Inc. ARQT 0001690298 Curran Terrie false C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE CA 91361 1 0 0 0 0 Common Stock 2026-08-27 4 M 0 11148 7.51 A 34674 D Common Stock 2026-08-27 4 S 0 11148 25.0294 D 23526 D Common Stock 2026-08-27 4 M 0 27052 8.63 A 50578 D Common Stock 2026-08-27 4 S 0 27052 25.0294 D 23526 D Stock Option (right to buy) 7.51 2026-08-27 4 M 0 11148 0 D 2033-05-31 Common Stock 11148 0 D Stock Option (right to buy) 8.63 2026-08-27 4 M 0 27052 0 D 2034-06-14 Common Stock 27052 0 D The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. The option is fully vested. /s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran 2026-08-28